You are here:

Frovatriptan (Migard)


Following a resubmission.

Frovatriptan (Migard) is accepted for use within NHS Scotland for treatment of the headache phase of migraine attacks with or without aura.

It is the seventh 5-HT1 agonist to be marketed in the UK for this indication. It is less effective at rapidly relieving migraine when compared with the most commonly prescribed drug in this class, but has a similar duration of effect. It is also less expensive than other 5-HT1 agonists.

Drug Details

Drug Name: Frovatriptan (Migard)
SMC Drug ID: 49/03
Manufacturer: A Menarini Pharmaceuticals UK Ltd
Indication: Headache phase of migraine attacks with or without aura
BNF Category:
Sub Category: 4.7 Analgesics
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 9 February 2004

Archived Advice

Full submission 4 July 2003